PAP
CGON icon

Persistent Asset Partners’s CG Oncology CGON Stock Holding History

Persistent Asset Partners’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Sell
4,250
-7,389
-63% -$483K 0.09% 164
2026
Q1 		$788K Sell
11,639
-704
-6% -$39.9K 0.29% 84
2025
Q4 		$512K Buy
+12,343
New +$511K 0.23% 124

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Persistent Asset Partners's CGON Position: Q2 2026 in Review

Persistent Asset Partners reduced its CG Oncology (CGON) stake by 63% in Q2 2026, selling an estimated $483K and leaving 4,250 shares worth $302K. The position accounts for 0.09% of the portfolio, ranked #164.

Persistent Asset Partners first reported a position in CGON in Q4 2025 and has held it in 3 quarters since. The position peaked at $788K in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Persistent Asset Partners held 4,250 shares of CG Oncology worth $302K as of Q2 2026.
  • Persistent Asset Partners sold 7,389 CG Oncology shares in Q2 2026, an estimated $483K.
  • CG Oncology made up 0.09% of Persistent Asset Partners's portfolio in Q2 2026, its #164 holding.
  • Persistent Asset Partners first reported a position in CG Oncology in Q4 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's CG Oncology position peaked at $788K in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.